



INVITATION

**Translating clinical evidence
into individualised treatment
decisions in advanced
prostate cancer**

FRIDAY 14 JUNE 2019

15:30-18:00

**Hilton Tallinn Park, FR. R. KREUTZWALDI 23,
TALLINN, 10147, ESTONIA**

Room name: Sydney

janssen  Oncology

PHARMACEUTICAL COMPANIES OF 



LEARNING OBJECTIVES

- Discuss the need for, and the clinical benefits of, earlier treatment in patients with advanced prostate cancer.
- Compare different treatment options for individual patients based on clinical evidence.

15:30–18:00 | 14 June 2019

TIME	SESSION	FACULTY
15:00–15:30	Coffee break	
15:30–15:50	Epidemiology of metastatic prostate cancer	Moderator dr. Mihhail Žarkovski, Urologist, Tartu University Hospital
15:50–15:55	Q&A	
15:55–16:40	Practical considerations in first-line treatment of metastatic castration-resistant prostate cancer (CRPC)	Prof. Mindaugas Jievaltas, Urologist, The Hospital of Lithuanian University of Health Sciences
16:40–16:45	Q&A	
16:45–17:30	Metastatic castration-resistant prostate cancer: the right patient at the right moment	Dr. Helis Pokker, Oncologist, The North Estonia Medical Centre
17:30–17:35	Q&A	
17:35–18:00	Discussion	Moderated by dr. Mihhail Žarkovski
18:00	Dinner	